Metabolic benefits associated with sibutramine therapy

International Journal of Obesity

Volumn 26, Issue , 2002, Pages S34-S37

  Krejs, G J ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

Lipids; Metabolic syndrome; Sibutramine; Type 2 diabetes; Uric acid

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; SIBUTRAMINE; URIC ACID;

BODY FAT; BODY WEIGHT; COMORBIDITY; CONFERENCE PAPER; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ACTIVITY; GLYCOSYLATION; HUMAN; LIPID BLOOD LEVEL; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT REDUCTION;

ADIPOSE TISSUE; APPETITE DEPRESSANTS; CYCLOBUTANES; DIABETES MELLITUS; HUMANS; LIPIDS; OBESITY; WEIGHT LOSS;

EID: 0036945863     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0802217     Document Type: Article

References (10)

1. Wing RR, Marcus MD, Epstein LH, Salata R. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabet Care 1987; 10: 563–566.
2. Rissanen A, Pekkarinen T, Heinanen T et al. Weight loss profile with sibutramine in obese patients with type 2 diabetes: a doubleblind, placebo-controlled study. Obes Res 1999; 7(Suppl 1): 93S.
3. Serrano-Rios M, Melchionda N, Moreno-Carretero E. Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy. Diabet Med 2002; 19: 119–124.
4. McNulty SJ, Ur E and Williams G for the Multicentre Sibutramine Study Group. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diab Care (Accepted for publication).
5. Van Gaal LF, Peiffer FW. The importance of obesity in diabetes and its treatment with sibutramine. Int J Obes Relat Metab Disord 2001; 25(Suppl 4): S24–S28.
6. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 2002; 346: 393–403.
7. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New Engl J Med 2001; 344: 1343–1350.
8. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WH, Van Gaal LF. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 2119–2125.
9. Van Gaal LF, Wauters MA, Peiffer FW, De Leeuw IH. Sibutramine and fat distribution: Is there a role for pharmacotherapy in abdominal=visceral fat reduction? Int J Obes Relat Metab Disord 1998; 22(Suppl 1): S38–S40.
10. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.